Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: Renal MRI and Advanced Biochemical Markers to Predict Progression in DKD Patients Treated With SGLT2i Primary and study completion pushed from Aug 2027 to Apr 2028 Mario Negri Institute for Pharmacological ResearchNot applicable NCT07270198
  2. Notable: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer Primary completion pushed from Jun 1, 2026 to May 1, 2027 Galzu Institute of Research, Teaching, Science and Applied TechnologyNot applicable NCT06045572
  3. Notable: Systematic Oral Feeding Education Program Primary and study completion pushed from Dec 19, 2025 to Dec 19, 2026 National Taiwan University HospitalNot applicable NCT06763497
  4. Notable: TL117 · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase changed: Phase 1/2 → Phase 1 Suzhou Junde Biotechnology Co., LtdPhase 1 NCT04843098
  5. Notable: Berobenatide · Urine Leakage and With Obesity or Overweight (VESPER-SUI) Recruitment opened PfizerPhase 3 NCT07932925
  6. Notable: 177Lu-NYM032 Injection · Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruitment opened Norroy Bioscience Co., LTDPhase 3 NCT07795268
  7. Notable: Zigakibart + Atrasentan · Primary IgA Nephropathy Recruitment opened Novartis PharmaceuticalsPhase 3 NCT07850752
  8. Notable: Efgartigimod · Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) Recruitment opened argenxPhase 2 NCT07760818
  9. Notable: Single-agent Therapy of BR113 for Injection · Advanced Solid Tumors Recruitment opened BioRay Pharmaceutical Co., Ltd.Phase 1 NCT07753590
  10. Notable: ABI-6250 · Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function Recruitment opened Assembly BiosciencesPhase 1 NCT07850999
  11. Notable: Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 · IRM Recruitment opened Norroy Bioscience Co., LTDPhase 1 NCT07768306
  12. Notable: Nutritional Supplementation on Actinic Purpura: A Pilot Study Trial status changed: Suspended → Withdrawn Standard Process Inc.Not applicable NCT06840574
  13. Notable: GRACE-DE · Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) Recruitment opened AstraZenecaNot specified NCT07882212
  14. Notable: BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4 Recruitment opened SynchroHealth LLCNot applicable NCT07421648
  15. Notable: Pediatric Sleep Study Recruitment opened Olly, PBCNot applicable NCT07932938
  16. Notable: IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Recruitment opened Shanghai Gynecologic Oncology GroupPhase 1 NCT07674615
  17. Notable: Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy · Atrial Fibrillation Recruitment opened China National Center for Cardiovascular DiseasesNot applicable NCT07762742
  18. Notable: Metabolic Changes Associated With Weight Gain After Treatment of Achalasia Recruitment opened Assaf-Harofeh Medical CenterNot specified NCT07334639
  19. Notable: Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial Recruitment opened Sichuan Cancer Hospital and Research InstitutePhase 2 NCT07775040
  20. Notable: Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery Recruitment opened Mayo ClinicPhase 4 NCT07570940
  21. Notable: Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery Recruitment opened Samsung Medical CenterPhase 4 NCT07397949
  22. Notable: Baricitinib · Cardiac Sarcoidosis Recruitment opened Stanford UniversityPhase 2 NCT06868381
  23. Notable: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) Recruitment opened UNC Lineberger Comprehensive Cancer CenterPhase 2 NCT07484139
  24. Notable: Tiprelestat Versus Placebo When Added to Standard of Care · Pulmonary Arterial Hypertension (PAH) Enrolling by invitation only Marlene Rabinovitch, MDPhase 2 NCT07601295
  25. Notable: Vaccine (STEMVAC) for Improving Survival · Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden Recruitment opened University of WashingtonPhase 2 NCT07721259